TITLE:
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

CONDITION:
Leukoplakia, Hairy

INTERVENTION:
Acyclovir

SUMMARY:

      To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr
      virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir
      in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease
      in the HL patient and compare to existing historical control data.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Topical antifungal therapy.

        Patient must have:

          -  Newly diagnosed clinical and histological hairy leukoplakia.

          -  Positive HIV antibody by licensed ELISA or Western blot.

        Exclusion Criteria

        Co-existing Condition:

        Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

        Concurrent Medication:

        Excluded within 2 weeks of study entry:

          -  Systemic antifungal treatment.

          -  Excluded within 6 weeks of study entry:

          -  Immunomodulators.

          -  Systemic antiviral treatment.

        Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.

        Prior Medication:

        Excluded within 2 weeks of study entry:

          -  Systemic antifungal.

          -  Excluded within 6 weeks of study entry:

          -  Immunomodulators.

          -  Systemic antiviral treatment.

          -  Excluded within 8 weeks of study entry:

          -  Zidovudine (AZT) or other antiretroviral therapy.
      
